Regular small incentives can improve adherence to ART

This article is more than 7 years old. Click here for more recent articles on this topic

The provision of regular low-value economic incentives can improve adherence to antiretroviral therapy (ART), according to research conducted in Uganda and published in the online edition of AIDS. People were eligible for prizes worth approximately $1.50 if they attended their clinic appointments or took at least 90% of the ART doses as evaluated using electronic monitoring.

“In this study we present evidence that it is feasible and effective to use small behavioral economics incentives to increase ART adherence,” comment the authors. “Our study suggests that designing incentives based on behavioral economic insights can increase their effectiveness, and get beyond the often at best mixed results of recent interventions aimed at behavioral change in the HIV field based on traditional, fixed incentives of relatively large monetary value.”

Longer follow-up of the intervention is now planned.

Glossary

control group

A group of participants in a trial who receive standard treatment, or no treatment at all, rather than the experimental treatment which is being tested. Also known as a control arm.

depression

A mental health problem causing long-lasting low mood that interferes with everyday life.

hypothesis

A tentative explanation for an observation, phenomenon, or scientific problem. The purpose of a research study is to test whether the hypothesis is true or not.

powered

A study has adequate statistical power if it can reliably detect a clinically important difference (i.e. between two treatments) if a difference actually exists. If a study is under-powered, there are not enough people taking part and the study may not tell us whether one treatment is better than the other.

sample

Studies aim to give information that will be applicable to a large group of people (e.g. adults with diagnosed HIV in the UK). Because it is impractical to conduct a study with such a large group, only a sub-group (a sample) takes part in a study. This isn’t a problem as long as the characteristics of the sample are similar to those of the wider group (e.g. in terms of age, gender, CD4 count and years since diagnosis).

Adherence is key to the success of ART. Missed doses or prolonged unscheduled treatment interruptions can lead to viral breakthrough and the emergence of drug-resistant virus. Many people find it hard to achieve the high levels of adherence which ART demands. Research examining whether the provision of fixed economic incentives of relatively high value (usually in cash) has a positive impact on health-associated behaviours among people with HIV has had mixed results.

An alternative incentive approach uses behavioural economics and involves the provision of regular small incentives for achieving health-related targets.

Investigators in Kampala, Uganda, designed a randomised study involving 144 ART-experienced adults to see if small incentives using the behavioural economics theory increased adherence to ART.

The study population was drawn from adults receiving care at Mildmay, Uganda. All were ART-experienced (minimum two years of therapy) and had documented adherence problems.

They were randomised to receive standard of care, or into one of two intervention groups. People in these intervention groups were eligible for prizes such as coffee mugs, umbrellas or water bottles for timely attendance at clinic appointments (group one) or for taking at least 90% of their ART doses, measured electronically using MEMS (group two).

The study is intended to last two years; the investigators reported on the first nine months.

Over half the participants had completed primary education, two-thirds were women and the average age was 39 years. Median monthly disposable income was the equivalent of $58, of which 5% was spent on travel to clinic appointments. Approximately 12% were physically limited because of their health and 65% reported feelings of depression or hopelessness.

Individuals in the control group had an overall adherence rate of 81%, compared to 88% among those in intervention group one and 87% for people in group two. These differences were of borderline significance.

However, further analysis showed that the impact of the interventions was most pronounced around the target 90% adherence threshold. Just 40% of people in the control arm were able to manage this level of adherence, compared to 63% of people in the two intervention groups. The effect was most pronounced among those whose adherence was monitored using the MEMS system.

“A larger, fully powered study is needed to confirm these early promising results and would allow the results to additionally detect demographic subgroup differences to shed light on the characteristics of patients most likely to benefit from the intervention,” suggest the authors. “In the current study, those with relatively high (but not optimal) adherence seem to be benefiting disproportionately from the intervention, which is in line with our hypothesis that for our study sample of treatment-mature clients motivational rather than structural barriers are addressed by the small incentives offered.”

References

Linnemayr S et al. Behavioral economic incentives to improve adherence to antiretrovirals: early evidence from a randomized controlled trial in Uganda. AIDS, online edition. DOI: 10.1097/QAD.0000000000001387 (2017).